Epstein-Barr virus associated tumors and drug repurposing
A new study published in the peer-reviewed OMICS: A Journal of Integrative Biology identified differentially expressed host and viral microRNAs (miRNAs) in six Epstein-Barr virus (EBV) associated tumors. The study reports several drug candidates for repurposing and targeting EBV latent infection: Glyburide, Levodopa, Nateglinide, and Stiripentol, among others. Click here to read the article now.
The authors, Anamika Thakur and Manoj Kumar, PhD, from the Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR), Chandigarh, India, note: “This is the first integrative analysis, to the best of our knowledge, in regard to the potential ...












